Showing posts with label medical cannabis. Show all posts
Showing posts with label medical cannabis. Show all posts

Saturday, October 8, 2022

Minnesota Medical Cannabis Program Petitions

 



I have written about this program in the past.  In Minnesota, we have a medical cannabis program that allows for the prescription of specific forms of cannabis for a list of what are seen as indications.  To get on that list is basically a review of opinions and the Commissioner. Even though this program runs like a mini-FDA, it does not have a standard for approving conditions for medical cannabis use.  And let’s face it - that is because the supporting evidence for using medical cannabis is very weak and in many if not most instances – non-existent. And as I have pointed out in the past – the evidence collected by the program is also weak.  As far as I know the program does not produce any detailed adverse drug effect information and a lot of that advice depends on the pharmacists dispensing the medical cannabis.

This year the conditions up for placement on the list of indications include opioid use disorder, obsessive compulsive disorder, and irritable bowel syndrome. I restricted my comments to the first two conditions and the rationale is very clear. In the case of opioid use disorder (OUD), it is a widespread drug epidemic at this point fueled by widespread availability of opioids and synthetic opioids. Even though physician prescriptions have decreased overdose deaths continue to increase on a year-to-year basis. The pattern of overdoses has also changed substantially since OUD has spread from metropolitan to rural areas. Thirty years ago, OUD and overdose deaths were practically unheard of in rural areas and now they are commonplace. There are effective treatment for OUD as listed in the letter that follows.  There is a problem with access to substance use disorder treatment.  Most states have practically no detoxification facilities.  Access to physicians who are prescribing medication assisted treatment (MAT) for OUD (MOUD) is also very limited.

Like most political movements in the country – there is no critical analysis of the various cannabis initiatives.  To me – it was obvious from the start that medical cannabis was a way to start building political consensus for legalization of cannabis. Adding more intoxicants to the environment is never a good idea – but the practical issue is that the lesson of alcohol prohibition was that it could not be done without increasing crime, corruption, and the health dangers of unregulated alcohol. So a medical cannabis initiative is really not a genuine attempt to treat medical conditions with cannabis.

On that basis – it is not surprising that there is significant overreach in finding conditions where medical cannabis can be used. OUD and OCD are just two more diagnoses on that list. I was informed that my comments will be added but the vast majority of comments are not by physicians and are basically testimonials to cannabis. The FDA receives a lot of criticism and they also elicit public commentary but there is a core body of scientific decision makers.

With the writing of this post President Biden just came out with a statement that he is going to pardon people who are incarcerated for simple possession of marijuana and encourage governors to do the same (1).  That may be easier said than done since there was also a news report that the majority of these people have additional complicating charges.  He also initiated a review process by Secretary of Health and Human Services and the Attorney General on the way marijuana is listed in the Control Substance Act schedule.  It is currently a Schedule I drug making it the most dangerous and without medical applications according to this ranking. That results in a large grey zone when it is legally prescribed in some states and approved for recreation use in others.  There are associated problems with banking due to the federal scheduling but in an election year when any number of people from both parties are tripping over each other to legalize it – it seems like a foregone conclusion that it will be rescheduled at the minimum.

The Minnesota legislature approved low dose cannabis edibles earlier this year. There is a question about whether that was done by mistake. This is another step toward the eventual legalization of cannabis in Minnesota and will probably lead to the extinction of the Medical Cannabis program.  This story also illustrates the confusion among legislators about the basic differences between raw materials and cannabinoid derivatives. My viewpoint is legalization of cannabis was the goal all along and the users of medical cannabis have objected to higher fees for the medical product and many prefer smoking cannabis rather than using other forms.

 

George Dawson, MD, DFAPA

 

1:  Statement from President Biden on Marijuana Reform October 7, 2022 Link.

2:  Miranda S.  Minnesota lawmakers voted to legalize THC edibles. Some did it accidentally.  July 2, 2022 Link.


The letter not in support of indications for opioid use disorder or obsessive compulsive disorder:

October 3, 2022

Office of Medical Cannabis
PO Box 64882
St. Paul, MN 55164-0882

To Whom It May Concern:

I am a Minnesota psychiatrist who recently retired from clinical practice. I continue to research and write about psychiatry.  I worked at one of the largest substance use disorder treatment facilities in the United States. Every person I saw had a substance use disorder (SUD) that was significant enough to need residential treatment. Alcohol use disorder was the most common followed by opioid use disorder (OUD).  I was also an adjunct professor and lectured on the epidemiology, assessment, and treatment of substance use disorders. Areas of focus included the neurobiology of SUD, opioid use disorders, chronic pain, and Attention Deficit~Hyperactivity Disorder. I did research on medication assisted treatment of alcohol use disorder and depression. 

As an SUD develops, there are several associated biases that lead to chronicity. The first is the euphorigenic effect or “high” that occurs with all substances. That becomes a permanent memory that all subsequent episodes of use are compared against. Tolerance to drug effects limits the ability to experience that same degree of euphoria.  That leads to attempts to use more or more powerful versions of the same drug. In the case of OUD, that has led to the use of more powerful opioids like fentanyl. A second bias is the idea that all emotions and reactions to stress can be controlled by external substances.  Cannabis, alcohol, and benzodiazepines are used for that purpose. In that situation, withdrawal symptoms are misinterpreted as anxiety or depression.   That leads to an additional substance being taken. Detoxification is required to determine a person’s baseline state and whether there is a treatable anxiety or depressive disorder. A third bias is that “I have a lot of time to quit.” Young people with severe SUD will often tell themselves: “I am only in my 20s, I can quit later and at that time go to work or school.” That prolongs their risk exposure and the associated morbidity and mortality. A fourth bias is people with SUD are not risk averse. In other words, if they knew a substance contained fentanyl and were risk averse, they would avoid it. This is not true. Many will seek out fentanyl products or products they know contain fentanyl in pursuit of getting high. That pursuit can get to the point that greater amounts of substances or more novel substances are used and they do not care what the outcome is. They are willing to risk a fatal outcome in pursuit of getting high.  Finally, withdrawal symptoms from substances create a negative reinforcement bias – substances need to be taken to avoid withdrawal symptoms.

Easy access to opioids is a major factor in the continuing opioid crisis and the “three waves” of this epidemic that are described by the CDC (1). There were several papers (3) published that suggested that medical cannabis use was associated with less opioid use. Those findings have not been validated over time.   There has been a study done showing that opioid use was more likely to increase rather than decrease (4) with cannabis use. That study is consistent with what I have seen in the clinic.  

To summarize:

1.  We are still in the midst of a 2 decades long opioid use epidemic that has produced significant overdose mortality and morbidity. 

2.  There are current FDA approved treatments (10 drugs in 3 categories) that have demonstrated ability to prevent opioid overdoses and treat opioid use disorder (2). 

3.  Suggesting that Minnesota residents with an opioid use disorder use cannabis with no proven treatment efficacy over the FDA approved medications that have efficacy presents a clear ethical problem considering the level of mortality associated with this disorder.

For these reasons medical cannabis should not be approved for opioid use disorder.

I am also recommending that medical cannabis not be approved for the treatment of obsessive-compulsive disorder. The bulk of my argument rests on the information that I submitted last year recommending no medical cannabis approval for generalized anxiety disorder. In that submission, I pointed out that for many people cannabis use leads to anxiety and panic attacks rather than alleviating them. Obsessive-compulsive disorder (OCD) has effective psychotherapies and medical therapies. In fact, psychotherapy is the primary treatment modality. We currently have a healthcare system that rations access to both psychotherapy and medical treatment. When the lack of clinical trials of cannabis in OCD is considered, the same ethical dilemma presents as in the case of opioid use disorder. Is cannabis approved for OCD because health care systems and government regulators refuse to provide access to proven methods of treatment?

In both the case of opioid use disorder and obsessive-compulsive disorder, neither should be an indication for medical cannabis for the above stated reasons.

Sincerely,

George Dawson, MD, DFAPA

Lino Lakes, MN

 

 

References:

1:  CDC.  Understanding the Epidemic:

https://www.cdc.gov/opioids/basics/epidemic.html

 

2:  FDA Information about Medication-Assisted Treatment (MAT):  https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat

3. Bachhuber MA, Saloner B, Cunningham CO, et al. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014;174:1668–1673.

4:  Olfson M, Wall MM, Liu SM, Blanco C. Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States. Am J Psychiatry. 2018 Jan 1;175(1):47-53. doi: 10.1176/appi.ajp.2017.17040413. Epub 2017 Sep 26.

 


Thursday, September 23, 2021

Is Medical Cannabis Overly Promoted In Minnesota?

 


Karl Marx wrote his famous metaphor about religion being an opiate for the proletariat in 1843:

“Religious suffering is, at one and the same time, the expression of real suffering and a protest against real suffering. Religion is the sigh of the oppressed creature, the heart of a heartless world, and the soul of soulless conditions. It is the opium of the people.”

He suggests in the next paragraph that the abolition of religion would rid people of the illusory happiness and it would be more consistent with the goal of real happiness for the people.  Marx’s formulation has not withstood the test of time. There is no more happiness now with widespread secularism than there was in Marx’s day.  Despite that fact - his metaphor survives and I thought about it quite a lot as I read through the Minnesota Medical Cannabis Program Report (MMCP) Anxiety Disorder Review.  The main difference of course is that cannabis is an equivalent metaphor only at the level of the idea of what medical cannabis can do.  When some writers suggest that religion can cause people to sleep and dream unrealistically, cannabis can physically do the same thing.  But it is promoted as doing many other things for many people – despite a profound lack of evidence.

The MMCP has been around for a number of years. I have taken the longstanding position that the medical cannabis concept is basically a way to legitimize cannabis and eventually get it legalized. I have also taken the position that physicians should not be involved in what is essentially a political maneuver.  The grandest aspect of that political maneuver has been the MMCP acting as a mini-FDA and coming up with their own indications for cannabis use. Initially, the idea was to use cannabis for the treatment of chronic pain and hospice care. I attended one of the early CME courses where most of the speakers were pain doctors and oncologists. Psychiatric input on these decisions has generally been minimal, despite the fact that psychiatric populations are at the highest risk from cannabis exposure and psychiatrists typically see most of the complications of cannabis.  The initiative to treat anxiety (in all forms) has not been approved by the MMCP and they state that was the reason for a more detailed look at the literature on cannabis as a treatment for anxiety and producing the report. 

Reading the report is an interesting exercise. It is not written very much from a scientific standpoint. They are very explicit about what they are considering as evidence.  For example they consider a literature search, a small panel of experts that does not really come to any consensus, and the experience of other states with medical cannabis and the indication of anxiety to be the basis for the report.  There are significant problems with all of those sources. 

 

The Research Matrix

At first the Research Matrix of papers included in the appendix looks impressive. There are 30 papers listing the reference, study type, total number of participants, dose and results.  Reading through the studies - some are single person case reports, some are reviews, and there are 15 studies listed as randomized controlled trials (RCTs). Looking at the RCTs there are probably one or two studies with an adequate number of participants to be adequately powered to show a statistical difference. Additional problems include the lack of an actual anxiety diagnosis.  In fact the diagnoses involved were frequently not anxiety related at all. Three observational studies at the end probably had the most merit and their results were equivocal. So the research studies really add nothing toward answering the question of whether medical cannabis should be used to treat anxiety and certainly nothing about the dose, delivery, or cannabis subtype.

Experience of Other States

Tables 1 summarizes the information about how other states have handled the question about medical cannabis and anxiety.  The states listed are Nevada, New Jersey, North Dakota and Pennsylvania.  In Nevada and North Dakota, the legislatures were petitioned to add anxiety (as DSM-5 Generalized Anxiety Disorder) to the medical cannabis formulary.  In New Jersey and Pennsylvania it was a commissioner decision. The Pennsylvania Secretary of Health was described as being “proactive” by suggesting that medical cannabis for anxiety was a “tool in the toolbox” and recommended duration of use, specific formulations, and avoidance in teenagers.  In all 4 states where cannabis was approved, anxiety quickly rose to the top or second most frequent indication for prescribing medical cannabis. None of the states collects any outcome data. 

What about other countries with more experience with cannabis like the Netherlands?  I contacted a colleague there who forwarded my questions to 2 other psychiatrists who were anxiety experts and doing active research in the area.  They responded that medical cannabis was not prescribed for anxiety and that there was a medical cannabis site for the Netherlands.  The site suggests that a CBD product is recommended. They had the same concerns about THC causing anxiety and psychosis.  A direct comparison of the indications for medical cannabis use comparing the Minnesota program to the Netherlands is included in the following table and linked directly to the respective web sites.

 

Medical Cannabis Qualifying Conditions

 

Minnesota

 

  • Cancer associated with severe/chronic pain, nausea or severe vomiting, or cachexia or severe wasting
  • Glaucoma
  • HIV/AIDS
  • Tourette syndrome
  • Amyotrophic lateral sclerosis (ALS)
  • Seizures, including those characteristic of epilepsy
  • Severe and persistent muscle spasms, including those characteristic of multiple sclerosis
  • Inflammatory bowel disease, including Crohn’s disease
  • Terminal illness, with a probable life expectancy of less than one year*
  • Intractable pain
  • Post-traumatic stress disorder
  • Autism spectrum disorder (must meet DSM-5)
  • Obstructive sleep apnea
  • Alzheimer's disease
  • Chronic pain
  • Sickle cell disease
  • Chronic motor or vocal tic disorder

 

 

The Netherlands

 

  • Pain, muscle cramps and twitching in multiple sclerosis (MS) or spinal cord injury;
  • nausea, loss of appetite, weight loss and weakness in cancer and AIDS;
  • nausea and vomiting due to medication or radiation treatment for cancer, HIV infection and AIDS;
  • long-lasting pain of a neurogenic nature (cause is in the nervous system) for example due to damage to a nerve pathway, phantom pain, facial pain or chronic pain that persists after shingles has healed;
  • tics in Tourette's syndrome;
  • treatment-resistant glaucoma

 

 

 Expert Consensus

In terms of the professional consensus, the participants were described as  3 psychiatrists, a pediatrician, a person in recovery, a primary care physician, and a marriage and family therapist. On a scale of recommendations, there was one vote for non-approval, one vote in favor of a limited pilot study and follow-up outcomes, one vote for neutral not opposed, three votes in favor of considering for generalized anxiety disorder, panic disorder, and agoraphobia. No consideration is given to the experience of the physicians or the asymmetry of expertise. It appears to be a political approach to neutralizing the opinion of the group of physicians (psychiatrists) who essentially are left treating the complications of cannabis use disorder.  Those complications include acute mania or psychosis, anxiety and panic, chronic depression and amotivational syndromes, and significant cognitive problems.  Cannabis obscures whether the patient has a true psychiatric diagnosis or not.  It also destabilizes psychiatric disorders. That is the common theme I noted above.  This is really not expert consensus – it is a man-on-the street poll.

Apart from the very weak lines of evidence, some of the conclusions in this document are even worse.  There are basically 6 common themes:

1:  Protect the brain: There are longstanding concerns about the new timetable for brain development extending into the mid to late 20s. This is a peak period for drug experimentation and heavy use of alcohol and most substances. There appears to be consensus on this theme and I would agree.

2:  Safer alternative to benzodiazepines: the rationale here is much rockier.  The authors in this case cite the increase in benzodiazepine overdose deaths in the state of Minnesota, but the quality of this data is not clear.  I took a look at the data and contacted the Minnesota Department of Health about it – specifically if opioids were excluded as a primary cause along with fentanyl being sold as benzodiazepines. I was informed by an epidemiologist that a T42.4 code was present and the coding is not mutually exclusive. In other words, more drugs may be involved and fentanyl may have been involved. The death certificates and toxicology confirmations are dependent on the county medical examiner. The accuracy of the data is therefore in question. There are clearly ways to safely prescribe benzodiazepines.  Benzodiazepines are research proven alternatives for severe anxiety when conventional treatments have failed as a tertiary medication and cannabis is not.

In terms of addiction risk, the risk with cannabis is 8-12% overall and 17% for people who start using cannabis in their teens (1-6).  That compares with an addiction liability of about 10% with benzodiazepines (7).  Benzodiazepines are used by people who are taking multiple addicting drugs to amplify the effect, treat withdrawal symptoms, and treat the anxiety and insomnia that accompanies chronic substance use or opioid agonist therapy.  This population is often acquiring benzodiazepines from non-medical sources. There is no real good evidence that medical cannabis will replace non-medical use of benzodiazepines in that setting, since benzodiazepines are easily acquired from non-medical sources.

3:  Therapy is the standard:  Therapy is not the standard. The standard is whatever works for a particular practice setting.  Psychiatrists see people who have already seen a therapist and quite probably a primary care physician where their anxiety was diagnosed with a rating scale. That means they will have failed therapy and at least one or two medication trials. Psychiatrists are not going to start treatment by repeating ineffective therapies. In many cases, substance use including cannabis use is the main reason for the anxiety disorder in the first place.

4: Health Equity:  This was perhaps the most unlikely reason for cannabis use. To emphasize how far this document goes off the rails I am going to quote this section directly:

 “Known disparities exist in the level of care available for anxiety disorder among historically disadvantaged communities. Medical cannabis may offer these individuals the option for an alternative to current medications, however this view was not shared by all participants.” (p.15)

Are the authors of this document really suggesting that disadvantaged communities should settle for a substance that has been inadequately studied, has known severe medical and psychiatric side effects, and is associated with higher rates of suicidal ideation and suicide attempts in these disadvantage communities (14) rather than providing them with standard care? That statement to me is quite unbelievable. It is the first time I have seen a recommendation to use a prescription substance to address a social problem.  It may happen by default – but if you really want to promote health equity equivalence evidence based treatments are the only acceptable standard.

When  "an alternative to current medications" is mentioned cost is not discussed as a factor. In my discussions with people who have received medical cannabis from the Minnesota dispensaries, high cost was often mentioned as a limiting factor. This current price list from one of the dispensing pharmacies shows that nearly all of their products are much more expensive than the generic antidepressants used to treat anxiety disorders.

5: Limited research:  Cannabis advocates point to the lack of research due to the fact that cannabis is a Schedule 1 compound. That means there is no known medical use and a high potential for abuse. Since certain compounds have been FDA approved for specific indications, I anticipate that these compounds will be rescheduled.  That is one of many hurdles in researching cannabis.  A few of the others would include the issue of subject selection (cannabis naïve or not), placebo controls, specific form (THC:CBD ratio), type of drug delivery, and a general methodology that would capture a good sample of persons with an anxiety disorder in adequate numbers for the trial.

6: Harm Reduction:  The authors suggest that medical cannabis could serve to limit exposure to other more harmful drugs obtained on the street to treat anxiety like benzodiazepines. There is no evidence that this would occur given the availability and preference for non-prescribed benzodiazepines.  The issue of polysubstance dependence is complex.  A significant number of opioid users also use benzodiazepines. Despite a black box warning about respiratory depression from using that combination, the FDA has been clear that the medications can be prescribed together. Further, a recent study suggests that retention in a methadone maintenance program was twice as likely if the patients received prescription benzodiazepines as opposed to non-prescription benzodiazepines (10).  No such data exists for cannabis.

In terms of substituting cannabis for benzodiazepines the only study I could find was a retrospective observational study of new patients in a cannabis clinic. Over the course of 2 months 30.1% were able to stop benzodiazepine use and at 6 months that number had increased to 45.2%.  These authors (11) conclude

“Without dependable safety data and evidence from randomized trials for this cohort, cannabis cannot be recommended as an alternative to benzodiazepine therapy.”

 The conclusion of this paper suggests the options of maintaining the status quo or no approval for anxiety, approve for a limited number of “subconditions” defined as specific anxiety disorders, or approve for anxiety disorders.  They list the pros and  cons associated with each approach but not much was added relative to the above discussion.  There are a few comments that merit further criticism. The risks of maintaining the status quo are seriously overstated.  From reviewing previous tabulated data from the MN Medical Cannabis program, it is unlikely that any meaningful real world data will be collected. It is not possible to collect non-randomized, uncontrolled data on a substance that is highly valued and reinforces its own use that has any meaning. The results will predictably be like the comments solicited by this program that are 96% favorable. There are similar speculative predictions of the direct consequences of not providing medical cannabis in terms of not seeking therapy if using cannabis off the street, suicides due to not tolerating SSRIs, and patient harm from “illicit use”. Similar speculation occurs throughout the remaining bullets points and there seems to be a strong pro-medical cannabis for anxiety disorders bias.

To summarize, I am not impressed with the Minnesota Medical Cannabis Program report on the use of medical cannabis for anxiety. It clashes with my 35 years of clinical experience where cannabis has been a major problem for the patients I treated in community mental health centers, clinics, substance use treatment centers, and hospitals. It suggests a great potential for a substance that has been around and used by man for over 7 millennia.  You would think with that history, man would have realized by now that it was a panacea for his most common mental health problem – anxiety. The report also ignores the commonest role of cannabis in American society and that is as an intoxicant and not a medication.  Physicians should not be prescribing intoxicants.  You don’t need a prescription to go to a liquor store and purchase alcoholic beverages. If the real goal is to get cannabis out to the masses, the option is legalization of cannabis not medical cannabis.

 

George Dawson, MD, DFAPA

 

References:

1:  Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2(3):244-268. doi:10.1037/1064-1297.2.3.244

2:  Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1-2):120-130. doi:10.1016/j.drugalcdep.2010.11.004

3:  Anthony JC. The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS, eds. Cannabis Dependence: Its Nature, Consequences and Treat:ment. Cambridge, UK: Cambridge University Press; 2006:58-105.

4: NIDA. 2021, April 13. Is marijuana addictive?. Retrieved from https://www.drugabuse.gov/publications/research-reports/marijuana/marijuana-addictive on 2021, September 13.

5:  Moss HB, Chen CM, Yi HY (2012). Measures of substance consumption among substance users, DSM-IV abusers, and those with DSM-IV dependence disorders in a nationally representative sample. J Stud Alcohol Drugs 73: 820–828

6:  Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R et al (2008). The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 103: 439–449 discussion 450–451.

7: Becker WC, Fiellin DA, Desai RA. . Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend. 2007; 90 2-3: 280- 7. DOI: 10.1016/j.drugalcdep.2007.04.009 PubMed PMID: 17544227.

 

Harm Reduction:

8: Okusanya BO, Asaolu IO, Ehiri JE, Kimaru LJ, Okechukwu A, Rosales C. Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review. Syst Rev. 2020 Jul 28;9(1):167. doi: 10.1186/s13643-020-01425-3. PMID: 32723354; PMCID: PMC7388229.

9: Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12624-12626. doi: 10.1073/pnas.1903434116. Epub 2019 Jun 10. PMID: 31182592; PMCID: PMC6600903.

10: Eibl JK, Wilton AS, Franklyn AM, Kurdyak P, Marsh DC. Evaluating the Impact of Prescribed Versus Nonprescribed Benzodiazepine Use in Methadone Maintenance Therapy: Results From a Population-based Retrospective Cohort Study. J Addict Med. 2019 May/Jun;13(3):182-187. doi: 10.1097/ADM.0000000000000476. PMID: 30543543; PMCID: PMC6553513.

11: Purcell C, Davis A, Moolman N, Taylor SM. Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis. Cannabis Cannabinoid Res. 2019 Sep 23;4(3):214-218. doi: 10.1089/can.2018.0020. PMID: 31559336; PMCID: PMC6757237.

 

Cannabis and Psychosis:

12: Kuepper R, van Os J, Lieb R, Wittchen H, Höfler M, Henquet C et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study BMJ 2011; 342 :d738 doi:10.1136/bmj.d738

13: Murray RM, Mondelli V, Stilo SA, Trotta A, Sideli L, Ajnakina O, Ferraro L, Vassos E, Iyegbe C, Schoeler T, Bhattacharyya S, Marques TR, Dazzan P, Lopez-Morinigo J, Colizzi M, O'Connor J, Falcone MA, Quattrone D, Rodriguez V, Tripoli G, La Barbera D, La Cascia C, Alameda L, Trotta G, Morgan C, Gaughran F, David A, Di Forti M. The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study. Schizophr Res. 2020 Nov;225:63-68. doi: 10.1016/j.schres.2020.01.011. Epub 2020 Feb 6. PMID: 32037203.

 

Cannabis Use and Suicide:

14:  Kelly LM, Drazdowski TK, Livingston NR, Zajac K. Demographic risk factors for co-occurring suicidality and cannabis use disorders: Findings from a nationally representative United States sample. Addict Behav. 2021 Nov;122:107047. doi: 10.1016/j.addbeh.2021.107047. Epub 2021 Jul 12. PMID: 34284313; PMCID: PMC8351371.

 

Cannabis Use and Life-Threatening Medical Problems:

15:  Ladha KS, Mistry N, Wijeysundera DN, Clarke H, Verma S, Hare GMT, Mazer CD. Recent cannabis use and myocardial infarction in young adults: a cross-sectional study. CMAJ. 2021 Sep 7;193(35):E1377-E1384. doi: 10.1503/cmaj.202392. PMID: 34493564.

16:  Parekh T, Pemmasani S, Desai R. Marijuana Use Among Young Adults (18-44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor Surveillance System Survey Analysis. Stroke. 2020 Jan;51(1):308-310. doi: 10.1161/STROKEAHA.119.027828. Epub 2019 Nov 11. PMID: 31707926.

17:  Shah S, Patel S, Paulraj S, Chaudhuri D. Association of Marijuana Use and Cardiovascular Disease: A Behavioral Risk Factor Surveillance System Data Analysis of 133,706 US Adults. Am J Med. 2021 May;134(5):614-620.e1. doi: 10.1016/j.amjmed.2020.10.019. Epub 2020 Nov 9. PMID: 33181103.

18:  Desai R, Fong HK, Shah K, Kaur VP, Savani S, Gangani K, Damarlapally N, Goyal H. Rising Trends in Hospitalizations for Cardiovascular Events among Young Cannabis Users (18-39 Years) without Other Substance Abuse. Medicina (Kaunas). 2019 Aug 5;55(8):438. doi: 10.3390/medicina55080438. PMID: 31387198; PMCID: PMC6723728.


Pharmacokinetics and Adverse Effects of Cannabis:

19:  Schlienz NJ, Spindle TR, Cone EJ, Herrmann ES, Bigelow GE, Mitchell JM, Flegel R, LoDico C, Vandrey R. Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. Drug Alcohol Depend. 2020 Mar 21;211:107969. doi: 10.1016/j.drugalcdep.2020.107969. Epub ahead of print. PMID: 32298998; PMCID: PMC8221366.

20: Spindle TR, Cone EJ, Goffi E, Weerts EM, Mitchell JM, Winecker RE, Bigelow GE, Flegel RR, Vandrey R. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend. 2020 Jun 1;211:107937. doi: 10.1016/j.drugalcdep.2020.107937. Epub 2020 Apr 1. PMID: 32247649; PMCID: PMC7414803.

21:  Spindle TR, Martin EL, Grabenauer M, Woodward T, Milburn MA, Vandrey R. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. J Psychopharmacol. 2021 Jul;35(7):786-803. doi: 10.1177/02698811211021583. Epub 2021 May 28. PMID: 34049452. 

22:  Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, Hayes E, Vandrey R. Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial. JAMA Netw Open. 2018 Nov 2;1(7):e184841. doi: 10.1001/jamanetworkopen.2018.4841. Erratum in: JAMA Netw Open. 2018 Dec 7;1(8):e187241. PMID: 30646391; PMCID: PMC6324384.


Vaping and Pulmonary Toxicology:

23:  Meehan-Atrash J, Rahman I. Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology. Chem Res Toxicol. 2021 Oct 8. doi: 10.1021/acs.chemrestox.1c00290. Epub ahead of print. PMID: 34622654.

24:  Tehrani MW, Newmeyer MN, Rule AM, Prasse C. Characterizing the Chemical Landscape in Commercial E-Cigarette Liquids and Aerosols by Liquid Chromatography-High-Resolution Mass Spectrometry. Chem Res Toxicol. 2021 Oct 5. doi: 10.1021/acs.chemrestox.1c00253. Epub ahead of print. PMID: 34610237.

25:  McDaniel C, Mallampati SR, Wise A. Metals in Cannabis Vaporizer Aerosols: Sources, Possible Mechanisms, and Exposure Profiles. Chem Res Toxicol. 2021 Oct 27. doi: 10.1021/acs.chemrestox.1c00230. Epub ahead of print. PMID: 34705462.

Epidemiology:

26: Lim CCW, Sun T, Leung J, et al. Prevalence of Adolescent Cannabis VapingA Systematic Review and Meta-analysis of US and Canadian StudiesJAMA Pediatr. Published online October 25, 2021. doi:10.1001/jamapediatrics.2021.4102

Prevalence of cannabis vaping by adolescents has recently increased for lifetime use, use in the past 30 days and use in the past year.

Maternal Cannabis Use and Anxiety in Offspring:

Rompala G, Nomura Y, Hurd YL. Maternal cannabis use is associated with suppression of immune gene networks in placenta and increased anxiety phenotypes in offspring. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2106115118. doi: 10.1073/pnas.2106115118. PMID: 34782458.

LaSalle JM. Placenta keeps the score of maternal cannabis use and child anxiety. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2118394118. doi: 10.1073/pnas.2118394118. PMID: 34789581.



Graphics Credit: The graphic at the top of this post is from Shutterstock per their standard user agreement.

 

 

Thursday, September 16, 2021

Letter to the Minnesota Medical Cannabis Program on an Anxiety Indication

 




The Minnesota Medical Cannabis program is considering anxiety and panic attacks as an indication for the use of medical cannabis in this state. Like several other states, there was a reluctance to legalize or just decriminalize cannabis and the legislature constructed a medical cannabis program that is very expensive for most people, does not allow for smoked cannabis products, and generally acts like a mini-FDA - approving the use of an non-FDA approved compound that has really not been adequately studied.  The current reasons are anxiety and panic attacks and it has failed several times for these conditions. This time they have an extensive report at this link that I will be critiquing this weekend. My longstanding position on medical cannabis is that it is essentially a way to get cannabis approved to eventually legitimize legalization or to have these compounds available in lieu of legalization. In other words, it is the next best thing to legalization.  The scope of the medical cannabis arguments are not compelling and if the regulators of the state of Minnesota believe that cannabis is that safe and efficacious - why don't they just legalize it without a medical indication?  In talking with people in the medical cannabis program - cost and inability to titrate the dose (by smoking) are common problems. Surveys by the Program suggest even more problems.

What follows is my brief letter to the public comments section on this issue. If you look at all of the comments - it reminds me of the public comments section at the FDA for electroconvulsive therapy and whether additional trials would need to be done to relicense those devices.  It was clear that those comments in favor of that process outnumbered the pro-ECT comments - but the FDA overruled the naysayers. It is not clear to me that cannabis advocates will be overruled by the Minnesota Cannabis program but I will write more about that in my critique.  

Public commentaries can be submitted to this email address: 

health.cannabis.addmedicalcondition@state.mn.us

Petition comments can be read at this address: 

https://www.health.state.mn.us/people/cannabis/petitions/docs/2021/commentsmedcond.pdf

The Anxiety Disorder Review (by the MN Medical Cannabis Program) can be read at this address:

https://www.health.state.mn.us/people/cannabis/petitions/anxietyreport.html

Comments should be submitted by October 1, 2021

----------------------------------------------------------------------------------------------------------------------------

I am a Minnesota psychiatrist who has practiced for 22 years as an acute care inpatient psychiatrist followed by 10 years as an addiction psychiatrist. Before that I was a community psychiatrist in Superior, Wisconsin for 3 years at a community mental health center. I am no longer affiliated with any of those institutions and this email is based on my cumulative clinical experience.

In those 35 years of practice, I have done thousands of comprehensive psychiatric evaluations that typically include an assessment of any associated substance use disorder. One of my standard questions in those assessments is "Were you ever a daily marijuana smoker?" In following up that question I ask about the duration and why they may have stopped. The typical reason for stopping is that they started to get high anxiety and panic attacks.  Depending on the degree of euphoria from cannabis - some people continue to use it and expect that their anxiety or other symptoms can be treated so that they can continue to use it.

 As an acute care psychiatrist, I saw many people who were psychotic or manic as either the direct effect of cannabis or because it exacerbated an underlying major psychiatric disorder.  In the outpatients that I have treated cannabis was associated with chronic depression and cognitive symptoms that were often seen by the patient as evidence that they needed treatment for attention-deficit/hyperactivity disorder.  In both scenarios, cannabis use was more than a psychiatric diagnosis - it led to these patients having significant impairment in their relationships, vocational achievement, and general ability to function. Some tried to stop and developed cannabis hyperemesis syndrome or other symptoms of withdrawal. 

As part of my comprehensive evaluations, every patient I saw was also assessed for suicide and aggressive potential. Populations of people seeing psychiatrists will be biased in that direction because in many settings suicidal and aggressive thinking is why they are scheduled to see us.  There is a clear link between cannabis use and increased suicidal thinking.  More recent research also suggests that  Black/African American, Hispanic/Latinx, and Native Americans were at elevated risk for suicidal ideation if they have a cannabis use disorder and  Black/African American and Hispanic/Latinx groups using cannabis were at higher risk for suicide attempts.

Many of the patients I see have complicated medical problems that can be compounded by cannabis use.  Cannabis has a significant hypotensive effect that typically triggers a rapid heartbeat and "heart pounding effect."  That is a potential problem for people with cardiovascular problems or who take antihypertensive medications.  In a recent large study of 18–44-year-olds, cannabis users (defined as use more than four times a month) were more than twice as likely to experience a heart attack. 

There are better and safer treatments for anxiety disorders. There are better and safer treatments for anxiety disorders that do not respond to first line treatments. I recommend against an anxiety or panic attack indication for medical cannabis because in the vast majority of people I have seen it caused significant anxiety and panic. It also obscures psychiatric diagnoses and considering that most people will not have access to a psychiatrist - will probably result in more medications to treat the cannabis induced symptoms.  At a time when there is more focus on suicide prevention, cannabis use is implicated in suicidal ideation and suicide attempts.  Finally when there has been concern about the lack of medical research on cannabis for positive effects, the negative effects are becoming more apparent. 

 Sincerely,

 

George Dawson, MD, DFAPA

References:

1:  Kelly LM, Drazdowski TK, Livingston NR, Zajac K. Demographic risk factors for co-occurring suicidality and cannabis use disorders: Findings from a nationally representative United States sample. Addict Behav. 2021 Nov;122:107047. doi: 10.1016/j.addbeh.2021.107047. Epub 2021 Jul 12. PMID: 34284313; PMCID: PMC8351371.

2:  Ladha KS, Mistry N, Wijeysundera DN, Clarke H, Verma S, Hare GMT, Mazer CD. Recent cannabis use and myocardial infarction in young adults: a cross-sectional study. CMAJ. 2021 Sep 7;193(35):E1377-E1384. doi: 10.1503/cmaj.202392. PMID: 34493564.

3:  Parekh T, Pemmasani S, Desai R. Marijuana Use Among Young Adults (18-44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor Surveillance System Survey Analysis. Stroke. 2020 Jan;51(1):308-310. doi: 10.1161/STROKEAHA.119.027828. Epub 2019 Nov 11. PMID: 31707926.

4:  Shah S, Patel S, Paulraj S, Chaudhuri D. Association of Marijuana Use and Cardiovascular Disease: A Behavioral Risk Factor Surveillance System Data Analysis of 133,706 US Adults. Am J Med. 2021 May;134(5):614-620.e1. doi: 10.1016/j.amjmed.2020.10.019. Epub 2020 Nov 9. PMID: 33181103.

5:  Desai R, Fong HK, Shah K, Kaur VP, Savani S, Gangani K, Damarlapally N, Goyal H. Rising Trends in Hospitalizations for Cardiovascular Events among Young Cannabis Users (18-39 Years) without Other Substance Abuse. Medicina (Kaunas). 2019 Aug 5;55(8):438. doi: 10.3390/medicina55080438. PMID: 31387198; PMCID: PMC6723728.


Graphic Credit:

Medical Cannabis graphic is from Shutterstock per their standard agreement.

Monday, June 10, 2019

Medical Cannabis Does Not Prevent Opioid Overdoses





The political aspects of medical cannabis are undeniable. The legalization of cannabis for recreational purposes had no traction with American politicians or voters until it was promoted as a miracle drug.  With that widespread promotion medical cannabis is now legal in 33 states and recreational cannabis is legal in ten.  The legalization arguments also suggested that the US was behind other countries of the world when there are only two countries – Canada and Uruguay – where it is completely legal for medical or recreational sale and purchase.  In the world, 22 of 195 countries have legalized medical cannabis with widely varying restrictions on its use. The Netherlands is often cited as an example of recreational cannabis use, but most Americans don’t realize that it is illegal for recreational use and tolerated for use and sale only in specially licensed coffee shops.  The promotion of cannabis as a solution to the opioid overuse and chronic pain problems can be seen as an extension of the political arguments for legalization that outpace any science to back them up.

There was probably no greater hype about the purported benefits of medical cannabis than early data suggesting that it might decrease the rate of opioid overdoses (1). The sequence of events was supposed to be opioid users tapering off of opioids or using lower equivalent amounts because of medical cannabis use.  The original study covered the time period from 1999-2010 and suggested that states with medical cannabis laws had a lower mean opioid overdose mortality and that the annual rates of overdose progressively decreased over time.  The authors conclusion was:  “Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates.”

Despite the usual caveats suggested by the authors in the original study the results of that study were heavily hyped by all cannabis promoters as was the discussion of many Internet forums.  The lay press, public, and politicians saw it as another reason to promote medical cannabis and recreational cannabis by association.

A study came out today in PNAS (2), that is an extension of the original data and it no longer comes to the same conclusion.  In this new study the authors replicated the opioid mortality estimates from the original study but when the data was extended from 2010 to 2017 – the improved opioid overdose mortality rates not only did not stay constant but they reversed themselves to that they were now on the average from -21% to +23%.  They provide an even more valuable analysis of this effect as spurious rather than a true positive or negative effect based on the low penetration of medical cannabis in the population at large (2.5%).  The authors focus on the problem of ecological fallacy – that is conclusions about individuals are drawn from aggregate data across the entire population.They point out that the states with the medical cannabis laws have a number of characteristics separating them from other states.  A recent good example of this fallacy was the New England Journal of Medicine (3,4) report that per capita chocolate consumption correlated with the number of Nobel Laureates in a particular country.  

This is a valuable lesson in scientific analysis. The political approach to the problem is all that most of the public sees. That approach is to grab any information that seems to agree with your viewpoint and run with it.  Big Cannabis and cannabis promoters have been doing this for almost 20 years now. The process of science on the other hand is slower and more deliberate.  It is not a question of a right answer but a dialogue that hopefully produces the right pathway. The authors of this study have added a lot to the dialogue about cannabis but also statistics and how statistical descriptions may not be what they seem to be. 

George Dawson, MD, DFAPA


References:

1: Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668–1673. doi:10.1001/jamainternmed.2014.4005 (full text)

2:  Shover CL, Davis CS, Gordon SC, Humphreys K.    Association between medical cannabis laws and opioid overdose mortality has reversed over time.  First published June 10, 2019 https://doi.org/10.1073/pnas.1903434116  (full text)

3: Messerli FH. Chocolate consumption, cognitive function, and Nobel laureates. NEngl J Med. 2012 Oct 18;367(16):1562-4. doi: 10.1056/NEJMon1211064. Epub 2012 Oct 10. PubMed PMID: 23050509.

4:  Pierre Maurage, Alexandre Heeren, Mauro Pesenti, Does Chocolate Consumption Really Boost Nobel Award Chances? The Peril of Over-Interpreting Correlations in Health Studies, The Journal of Nutrition, Volume 143, Issue 6, June 2013, Pages 931–933, https://doi.org/10.3945/jn.113.174813


Attribution:

Above figure is from the original article (reference 2): "This open access article is distributed under Creative Commons Attribution-Non Commercial No Derivatives License 4.0 (CC BY-NC-ND).y"  See this link for full conditions of this license.



Sunday, March 10, 2019

Will Physicians Be Superfluous In The Recreational Cannabis World?




When it comes to advising people to use cannabis for various problems I think the answer is yes.    Only a small fraction of people who can access recreational cannabis will be asking physicians for advice on using these products. There are a confluence of reasons but basically they involve cultural factors, political factors, the marketing of cannabis products, expense, and the inconvenience of seeing a doctor for advice and prescriptions when you can get advice from other people including dealers and producers.  I would go as far as saying that many of the advisors will be prominent media figures giving advice on the use of cannabis and expanding the marketplace.  It follows that the education of physicians should take these factors into account.

It is easy to get into disagreements on Twitter.  I think most physicians including myself are fairly easy to disagree with because we are not invested in “winning” an argument. As a psychiatrist I know that I certainly am not going to win against an ideologue or somebody was interested in calling me names. This week I got into a disagreement about the role of physicians in medical cannabis. The controversy was sparked by an article written by a medical student about why medical cannabis should be discussed in medical schools.  Any reader of this blog knows that my position has been that medical cannabis is basically a political lever to promote the widespread legalization of so-called recreational marijuana. I also believe that every state in the United States will eventually have recreational marijuana. I don't argue that point - I know it will happen.  At that point, we will have a better assessment of the risks involved with this policy and they will be significant.

The issue this week was a post suggesting that medical students and physicians should have more training in “medical cannabis”. My position was that if most states go the way that Colorado went physicians will be entirely superfluous in that process. It comes from my knowledge of interaction of American culture and the wide availability of recreational cannabis products in the state of Colorado. Medications especially those that are self-reinforcing or put more basically the ones that can get you high, attain mythical status in the American culture.  Practically everyone I know hoards opioids.  That supply of oxycodone or hydrocodone that is typically given for some type of injury used to be held onto for years. Neighbors would trade pills back and forth over the fence. Opioids no longer sit in a medicine cabinet for years as people actively seek out opioids to get high or sell.  Most Americans have a set idea of what opioids they would like for pain and that decision-making process is complex based on their experience and also what they’ve heard from other people.  The reality of that process is quite different.

In my opinion pain has been inadequately studied and continues to be inadequately studied. The concept of “self-medication” is at the top of that list. I usually hear about it in the form of this sentence:

“Look Doc, if you can’t get rid of this (anxiety, depression, insomnia, pain, fatigue, distractability) I know how to get rid of it for at least four hours.”

When I inquire about the method it invariably comes back to alcohol or some type of consciousness altering drug. I use the term consciousness altering because the drugs used are not necessarily addictive. A good example is a combination of antihistamines and muscle relaxants to cause a state of delirium and sedation. Alcohol is frequently used as a way to address chronic pain. The medical cannabis initiative basically started around the issue of chronic pain and terminal pain. From there it has expanded indications in those states that list their own like Colorado and Minnesota. A lot of people address the issue of chronic pain by altering their conscious state. I certainly have no problem with that in certain circumstances but it is a major unaddressed dimension in the treatment of chronic pain.

The American Society of Addiction Medicine (ASAM) has a lengthy position statement (1) on the physician’s role in medical cannabis. They review the need for scientific study and a regulatory process that will provide pure and consistent formulations from companies in a similar manner to the pharmaceutical industry. It is the only way to come up with standardized dosing for specific conditions.  The only problem I have with that statement is that it is fairly naive to think that people with a choice between purchasing high cost pharmaceutical grade medical cannabis and recreational cannabis that claims to have the same cannabinoid content will choose the former whether it is “prescribed” or not.

That leads me to what I see as the role for physicians in a society that has widespread availability of recreational cannabis. Colorado is a good case in point. Looking at what cannabinoid products are available in a Colorado gas station, it is hard to imagine that people will be consulting physicians for what products to use. I recently found a web site for Colorado gas station cannabis with a wide range of smokable and edible cannabis products.  The edible products contained up to 250 mg THC per bar.  Physicians currently have the role of certifying conditions for people who will get access to medical cannabis. In Minnesota advice about medical cannabis comes from the pharmacists dispensing it and not from physicians. There is widespread advice available on the Internet about how any interested user could start using cannabis.

All of these factors, lead me to conclude that there will be a very limited role for physicians in recommending cannabis or prescribing it. There have been limited medical studies of cannabis and limited indications. There are basically two FDA approved applications and even those medications will be obsolete when people have access to the recreational and less expensive forms. There is no logic at all to declaring a botanical product is on the one hand “medical” and on the other hand “recreational”.

A larger role for physicians will be in the treatment of the medical complications from cannabis and people who become addicted to it.  As millions and millions of people start using legal cannabis – the number of people addicted to it will also increase.

The best way to address cannabis in a medical school curriculum doesn’t require an extensive course in medical cannabis for an ever-increasing political list of indications.  It should not teach medical students that they are going to have a central role in the acquisition and prescription of cannabis.  It can be done in the following courses:

1.  Basic science: neuroanatomy and neurophysiology – the endocannabinoid system’s critical role in basic physiology and clinical correlations.

2.  Basic science: pharmacology – detailed pharmacology of cannabinoids.

3.  Addiction course- there needs to be a basic 2-week course added to the medical school curriculum on addiction and the prescription of drugs that reinforce their own use with necessary risk mitigation techniques.  Many medical schools have a 6-week course in psychiatry that is usually based on an inpatient unit.  I recommend adding two weeks to that with experience in an addiction clinic. I currently work in a program where we provide two week training programs to residents, medical students, and physicians for this purpose.

4.  Elective course - experience in specialty programs where there may be more cannabinoid use (pain clinics, palliative care, toxicology) that can be tailored to a student’s interest.

5.  Clear identification of resources for further study - during lectures I always mention the major addiction texts and their organization. Additional state-of-the art references could be posted in a self study syllabus - primarily because a clinical focus would not allow enough time to cover the necessary basic science.

6.  Advice on the regulatory burden - in the foreseeable future that means familiarity with the statutes and regulations in each state.  Medical schools generally do not teach these practical aspects of medical care.  States recognize that physicians can't prescribe a CSA Schedule 1 drug, and limit the physicians role to certifying the conditions that qualify the patient for medical cannabis. Some states require physicians to get approval for that role.  That seems like overkill to me. Any medical record with the qualifying condition listed should lead to certification and would probably be more objective. 

Any effort beyond what I have listed above is probably unrealistic based on the fact that this is (along with supervised practice) is the basic approach to any medication that physicians prescribe.  I am not aware of any medical school initiatives to intensify the training for opioids, benzodiazepines, or stimulants but would appreciate hearing about any of those courses. In the course where I teach, we see medical students, residents, and physicians from all over the US and Canada.

In closing are there possibly ways where physicians will end up in a more central role? Only if the FDA and other regulatory bodies put them there.  For example, in my post on Epidiolex I asked about the patentability of CBD products, specifically this one that was an extraction product of cannabis.  Physicians prescribing these FDA products need to learn to prescribe them like any new product, but is there a chance that FDA approved and patented cannabis products are a threat to the products available for recreational and medical use from dispensaries?  There is currently a story circulating saying that the FDA is going to ban all CBD oil use except for Epidiolex and it will cost all users $32, 500 a year. That would favor the pharmaceutical industry but I don't think that will happen. It is more likely that other products designed to affect the endocannabinoid system will be developed like standard pharmaceuticals and that will lead to physician prescribing - if there is anyone left at that point who is not using recreational cannabis.



George Dawson, MD, DFAPA




Supplementary Information:

I recently encountered an interesting twist by a cannabis advocate in a state where recreational cannabis is not yet legal and medical cannabis is strictly controlled as non-smokable products.  He argued that the terms recreational cannabis and medical cannabis should be changed to cannabis for non-prescription and prescription use.  He argued that this would normalize the political process since nobody designates alcohol as recreational or medical. The obvious reason is that alcohol has extremely limited roles as a medication.  The term medical cannabis may have lost some of its luster as a politically correct approach.    




References:

1:  The Role of the Physician in “Medical” Marijuana. ASAM Public Policy Statement (2010) Link


Graphic:

Downloaded from Shutterstock per their standard licensing agreement.